Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 3,897 shares at $171.15 ($678K) on 2015-02-10, disclosed to the SEC on 2015-02-12.
Open-market sale of $678k ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $171.15 | 1,990 | $341K | 50.2% |
| 2 | $176.91 | 1,907 | $337K | 49.8% |
| Total | $173.97 avg | 3,897 | $678K | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |